BIOE · Bio Essence Corp
Substantial doubt about the company's ability to continue as a going concern.
“The Company also had an accumulated deficit of $9,077,623 as of June 30, 2026. These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $2.91M | $1.9M | $323.94K | $551.51K | $621.59K | $887.98K | $958.7K | |
| $882.71K | $469.15K | $106.86K | $274.06K | $293.26K | $589.66K | $731.41K | |
| $2.03M | $1.43M | $217.08K | $277.45K | $328.33K | $298.32K | $227.29K | |
| — | 75.28% | 67.01% | 50.31% | 52.82% | 33.6% | 23.71% | |
| $459.1K | $497.81K | $676.52K | $345.59K | $763.15K | $1.08M | $907.89K | |
| — | $235 | $235 | $235 | $235 | $6349 | $10.72K | |
| $103.78K | $235 | $911 | $4793 | $14.51K | $35.8K | $33.28K | |
| $489.83K | $528.4K | $676.52K | $345.59K | $839.46K | $1.16M | $1.06M | |
| $1.54M | $900.01K | -$459.44K | -$345.59K | -$511.14K | -$857.53K | -$832.57K | |
| — | 47.43% | -141.83% | -62.66% | -82.23% | -96.57% | -86.84% | |
| $1.64M | $900.25K | -$458.53K | -$340.8K | -$496.63K | -$821.73K | -$799.29K | |
| -$704 | $2186 | $2153 | $17.34K | $14.13K | $38.56K | $41.9K | |
| -$1180 | -$3014 | -$1.11M | -$57.41K | -$5332 | -$9699 | -$24.4K | |
| $1.54M | $897K | -$1.56M | -$403K | -$525.38K | -$644.26K | -$592.54K | |
| — | $800 | $800 | $1600 | $2500 | $3300 | $3300 | |
| $1.52M | $896.2K | -$1.31M | -$971.88K | -$809.68K | -$647.56K | -$595.84K | |
| — | 47.23% | -404.02% | -176.22% | -130.26% | -72.93% | -62.15% | |
| USD/shares | -$0.03 | — | -$0.03 | -$0.03 | -$0.02 | -$0.02 | — |
| USD/shares | -$0.03 | — | -$0.03 | -$0.03 | -$0.02 | -$0.02 | — |
| shares | — | 38.01M | 38.01M | 33.95M | 33.01M | 33.01M | 33.03M |
| shares | — | 38.01M | 38.01M | 35.95M | 33.01M | 33.01M | 33.03M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 32 similar-size Drug Manufacturers - Specialty & Generic companies (of 95 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue from OEM Services | $1,896,350 | $282,752 | — | — | — |
| Shipping and Delivery Income | $1,216 | $3,773 | — | — | — |
| Sales of Goods | — | $37,415 | — | — | — |
| Manufacture Service Revenue | — | — | $364,167 | $113,918 | — |
| Sales of Goods | — | — | $621,590 | $774,066 | $958,700 |